Physician profile
John T Pearson
NPI 1962400655
$6,982.08
in general payments reported to CMS, 2019-2025
29 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,527 · 2022: $1,301 · 2023: $1,091 · 2024: $1,740 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,088 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,088.40 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,425.87 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $972.06 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $821.87 | 2021-2025 | |
| Lilly USA, LLC | $644.69 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $604.60 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $344.52 | 2021 | |
| Pfizer INC. | $321.22 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $279.39 | 2022 | |
| Abbott Laboratories | $226.48 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Dexcom, INC. | $211.06 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.54 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $161.84 | 2023-2025 | Veozah |
| Amgen INC. | $133.49 | 2021-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $96.19 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $93.12 | 2024-2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.36 | 2024-2025 | Caplyta |
| Genentech USA, INC. | $77.60 | 2021-2022 | |
| Shield Therapeutics INC | $55.32 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $40.97 | 2024-2025 | Rexulti |
| Optinose US, INC. | $33.11 | 2021 | |
| Esperion Therapeutics, INC. | $30.86 | 2022-2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $26.67 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $23.12 | 2024 | Austedo Xr |
| Hologic Sales and Service, LLC | $21.15 | 2024 | Aptima |
| Xeris Pharmaceuticals, INC. | $20.31 | 2023 | Gvoke Hypopen |
| Tactile Systems Technology INC | $19.10 | 2024 | Flexitouch Plus, Entre Plus |
| Novartis Pharmaceuticals Corporation | $15.24 | 2022 | |
| Alkermes, INC. | $14.53 | 2022 | |
| Eisai INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.